Tag: Tdf

The World Health Organization estimated that 254 million people were living with chronic hepatitis B (HBV) in 2022, a condition that can lead to severe liver damage [1.6.2]. A key question for patients is: **can tenofovir reverse liver damage** caused by this virus?

Over 250 million people worldwide are affected by chronic hepatitis B (CHB), a condition for which tenofovir is a frontline treatment. This raises a critical question for many patients and those at risk: **Is tenofovir lifelong?** The answer is not simple and depends on the specific viral infection being treated.

Studies have shown that for each year of exposure to tenofovir disoproxil fumarate (TDF), the risk of proteinuria can increase by 34%, while the risk of chronic kidney disease (CKD) can increase by 33%. The timeline for tenofovir to damage kidneys is highly variable, ranging from months to years, depending on the specific formulation, patient risk factors, and concurrent medications.

Clinical trials have shown that Vemlidy (tenofovir alafenamide, TAF) provides similar antiviral efficacy to Viread (tenofovir disoproxil fumarate, TDF) for chronic hepatitis B at a dose less than one-tenth that of Viread. This significant difference in dosage efficiency and safety profile is at the heart of the question: why is Vemlidy better than Viread?

For antiretroviral-naive HIV-1 patients, tenofovir (TDF) containing regimens demonstrated virologic suppression rates of approximately 90% at 48 weeks in clinical trials. This impressive efficacy highlights a key aspect of the success rate of tenofovir in managing viral infections, though specific outcomes vary based on the treated condition, patient adherence, and the specific tenofovir formulation used.